TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis ; day:07 ; month:01 ; year:2025
South Asian journal of cancer ; (07.01.2025)
- Contributor
-
Joarder, Ritam
Patel, Dhwani
Tiwari, Atul
Choudhary, Jatin
Vana, Pranaya
Shenoy, Vallish
Mer, Neha
Ramaswamy, Anant
Bhargava, Prabhat
Ostwal, Vikas
- DOI
-
10.1055/s-0044-1801347
- URN
-
urn:nbn:de:101:1-2502271038370.948295552446
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Joarder, Ritam
- Patel, Dhwani
- Tiwari, Atul
- Choudhary, Jatin
- Vana, Pranaya
- Shenoy, Vallish
- Mer, Neha
- Ramaswamy, Anant
- Bhargava, Prabhat
- Ostwal, Vikas
Other Objects (12)
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease
Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Intra Peritoneal Chemotherapy in Epithelial Ovarian Cancers
TAS
TAS
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease
Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Intra Peritoneal Chemotherapy in Epithelial Ovarian Cancers
TAS
TAS
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease
Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Intra Peritoneal Chemotherapy in Epithelial Ovarian Cancers
TAS